Development of GPR124 Wildtype and Knockout Brain Endothelial Reporter Cells

The National Cancer Institute seeks parties interested in co-discovery and co-development of safe and effective TEM5 agonists and/or antagonists that modulate WNT signaling.IC: NCINIH Ref. No.: E-079-2015Advantages: TEM5 is selectively upregulated in cerebrovasculature of tumorsTEM5 inhibitors have less potential for causing side effects compared to other Wnt signaling inhibitorsApplications: High throughput screen for TEM5 (GPR12) inhibitorsDevelopment Status: Discovery (Lead Identification)Updated On: Dec 7, 2017Provider Classifications: Publications: Licensing Contacts: Lead Inventor: Inventor IC: NCIInventor Lab URL: http://ccr.cancer.gov/brad-st-croixInv Is lead: LPM Phone: [phone]LPM Email: [e-mail] Classification: Research MaterialsDTDT Description: Research MaterialsPublication Link: http://www.ncbi.nlm.nih.gov/pubmed/25558062https://www.ncbi.nlm.nih.gov/pubmed/21421844Publication Caption: PMID:25558062PMID:21421844Publication Title: Posokhova E et al.Cullen M et al.Collaboration Sought: YesInstitute or Center: NCICollaboration Opportunity: Licensing and research collaborationInventor First Name: BradInventor Last Name: St. Croix

Source: NIH OTT Licensing Opportunities - December 8, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research